Q1 26 EPS
$7.79
BEAT +2.42%
Est. $7.61
Q1 26 Revenue
$68.49B
BEAT +3.46%
Est. $66.20B
vs S&P Since Q1 26
-11.0%
TRAILING MARKET
CI -3.4% vs S&P +7.6%
Market Reaction
Did CI Beat Earnings? Q1 2026 Results
The Cigna Group delivered a strong start to 2026, posting first-quarter adjusted earnings of $7.79 per share, up from $6.74 a year ago, marking the company's fourth consecutive quarter of beating consensus EPS estimates. Total revenues climbed 5% yea… Read more The Cigna Group delivered a strong start to 2026, posting first-quarter adjusted earnings of $7.79 per share, up from $6.74 a year ago, marking the company's fourth consecutive quarter of beating consensus EPS estimates. Total revenues climbed 5% year-over-year to $68.49 billion, with Evernorth Health Services serving as the primary engine, its Specialty and Care Services unit driving a 20% surge in pre-tax income on robust specialty volume growth and rising biosimilar adoption. Adjusted income from operations rose 12% to $2.06 billion, while GAAP net income came in at $1.65 billion, or $6.26 per share, compared to $1.32 billion, or $4.85 per share, in the prior-year period. Cigna Healthcare's medical care ratio improved meaningfully to 79.8% from 82.2%, aided by the exit from Medicare businesses completed in early 2025. Encouraged by the momentum, management raised its full-year 2026 adjusted income from operations outlook by $0.10 to at least $30.35 per share, with Cigna Healthcare's segment target lifted by $25 million to at least $4.53 billion.
Key Takeaways
- • Evernorth Health Services revenue growth driven by drug mix changes in Pharmacy Benefit Services and strong specialty volume growth in Specialty and Care Services
- • Cigna Healthcare adjusted pre-tax income increased 18% driven by improved margins in U.S. Employer and Individual and Family Plan businesses
- • Increased generic and biosimilar adoption lowering costs for clients and patients
- • Premium rate increases to cover expected increases in medical costs
- • Improved SG&A expense ratio reflecting business mix shift and operating efficiency
- • Medical care ratio improved to 79.8% from 82.2% primarily reflecting the HCSC transaction impact
CI YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
CI Revenue by Segment
With YoY comparisons, source: SEC Filings
“We continue to improve how people experience health care, leveraging innovation and technology to make it more personalized, more transparent and easier to navigate.”
— David M. Cordani, Q1 2026 Earnings Press Release
CI Earnings Trends
CI vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CI EPS Trend
Earnings per share: estimate vs actual
CI Revenue Trend
Quarterly revenue: estimate vs actual
CI Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | — | $7.78 | — | $71.67B | — |
| Q1 26 BEAT | $7.61 | $7.79 | +2.42% | $68.49B | +3.46% |
| Q4 25 BEAT FY | $7.88 | $8.08 | +2.50% | $72.47B | +4.91% |
| FY Full Year | — | $29.84 | — | $274.90B | — |
| Q3 25 BEAT | $7.64 | $7.83 | +2.47% | $69.75B | +4.50% |
| Q2 25 BEAT | $7.15 | $7.20 | +0.65% | $67.18B | +7.30% |
| Q1 25 BEAT | $6.35 | $6.74 | +6.17% | $65.50B | +8.48% |